NR2C2AP: A Potential Drug Target and Biomarker for TR4 Transactivation

Target Name: NR2C2AP

NCBI ID: G126382

NR2C2AP

NR2C2AP: A Potential Drug Target and Biomarker for TR4 Transactivation

Abstract:

TR4 is a key transcription factor that plays a crucial role in the development and maintenance of cancer. NR2C2AP is a repressor for TR4 transactivation that has been identified as a potential drug target and biomarker. This article discusses the mechanism of action of NR2C2AP, its potential as a drug target, and its potential as a biomarker for cancer.

Introduction:

Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences. TR4 is a transcription factor that plays a crucial role in the development and maintenance of cancer. It has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancers.NR2C2AP is a repressor for TR4 transactivation that has been identified as a potential drug target and biomarker for cancer.

Mechanism of Action:

NR2C2AP is a protein that contains multiple domains, including a N-terminal domain, a T-terminal domain, and a C-terminal domain. The N-terminal domain contains a putative RNA binding domain (PBD), which is known to be involved in protein-RNA interactions. The T-terminal domain contains a leucine zeta-hydroxylase (LZH) domain, which is known to be involved in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis. The C-terminal domain contains a G-quadruplex DNA-binding motif, which is known to be involved in DNA-protein interactions.

NR2C2AP has been shown to function as a repressor for TR4 transactivation. TR4 is a transcription factor that plays a crucial role in the development and maintenance of cancer. It has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancers.NR2C2AP has been shown to inhibit the activity of TR4, thereby repressing its transcriptional activity.

Potential as a Drug Target:

NR2C2AP has been identified as a potential drug target for cancer. Its PBD has been shown to interact with various proteins, including the protein kinase activating receptor (PARP) and the nuclear factor of activated T cells (NFAT). NR2C2AP has also been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis. Its LZH domain has been shown to be involved in the regulation of DNA-protein interactions, which could potentially lead to new insights into its function in cancer.

Potential as a Biomarker:

NR2C2AP has also been shown to serve as a potential biomarker for cancer. Its expression has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. NR2C2AP has also been shown to be a useful biomarker for tracking the effectiveness of anti-cancer drugs. Its expression has been shown to be reduced in response to chemotherapy, which could potentially lead to new insights into its role in cancer treatment.

Conclusion:

NR2C2AP is a repressor for TR4 transactivation that has been identified as a potential drug target and biomarker for cancer. Its N-terminal domain, T-terminal domain, and C-terminal domain have been shown to function as a repressor for TR4 transactivation. PBD has been shown to interact with various proteins, including the protein kinase activating receptor (PARP) and the nuclear factor of activated T cells (NFAT). NR2C2AP has also been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis. Its LZH domain has been shown to be involved in the regulation of DNA-protein interactions, which could potentially lead to new insights into its function in cancer. Its expression has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. NR2C2AP has also been shown to be a useful biomarker for tracking the effectiveness of anti-cancer drugs. Its expression has been shown to be reduced in response to chemotherapy, which could potentially lead to new insights into its role in cancer treatment. Further research is needed to fully understand the mechanism of action of NR2C2AP as a drug target and biomarker for cancer.

Protein Name: Nuclear Receptor 2C2 Associated Protein

Functions: May act as a repressor of NR2C2-mediated transactivation by suppressing the binding between NR2C2/TR4 and the TR4-response element in target genes

The "NR2C2AP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR2C2AP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets